Articles: chronic.
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: QVA149 is a once-daily dual bronchodilator containing a fixed-dose combination of the long-acting β2-agonist (LABA) indacaterol and long-acting muscarinic antagonist (LAMA) glycopyrronium (NVA237), for the treatment of chronic obstructive pulmonary disease (COPD). The BEACON study evaluated the efficacy and safety of QVA149 compared with the concurrent administration of indacaterol and glycopyrronium (IND+GLY). ⋯ The study demonstrated that QVA149 provides benefits of dual bronchodilation in a single inhaler device, making it a more convenient treatment option for patients with moderate-to-severe COPDDISCLOSURE: Ronald Dahl: Consultant fee, speaker bureau, advisory committee, etc.: In the past 3 years, Professor Dahl has received compensation for consulting with Boehringer-Ingelheim, Novartis, Vectura, Roche, Elevation Pharma and Norpharma; has undertaken research funded by AstraZeneca, Boehringer- Ingelheim, C hiesi, GlaxoSmithKline, Novartis, ALK-Abello and Stallergenes; has participated in educational activities sponsored by AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, ALK-Abello, Novartis, Almirall. Dalal Jadayel: Employee: Novartis Employee Vijay Alagappan: Employee: Novartis Employee Hungta Chen: Employee: Novartis Employee Donald Banerji: Employee: Novartis EmployeeClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.
-
Late Breaking AbstractsSESSION TYPE: Slide PresentationPRESENTED ON: Saturday, March 22, 2014 at 09:00 AM - 10:00 AMPURPOSE: Human immunodeficiency virus seropositivity (HIV+) has been considered a contraindication to lung transplantation (LT) primarily due to potential risks of iatrogenic immunosuppression. With the recent passage of the HIV Organ Policy Equity (HOPE) Act on November 21, 2013, the donation of HIV+ organs for transplant in HIV+ recipients is now legal in the USA. As a result there may be an increase in donors for HIV+ recipients. However, there remains only one fully published case report of LT in an HIV+ patient, limiting the evidence base with which to guide medical decision making. We report 3 HIV+ patients at two different medical centers who underwent LT. ⋯ The following authors have nothing to disclose: Ryan Kern, Harish Seethamraju, Paul Blanc, Neeraj Sinha, Matthias Loebe, Jeffrey Golden, Jasleen Kukreja, Scott Scheinin, Steve Hays, Kleinhenz Mary Ellen, Leard Lorri, Charles Hoopes, Jonathan SingerNo Product/Research Disclosure Information.
-
Slide PresentationsPRESENTED ON: Monday, March 24, 2014 at 09:00 AM - 10:00 AMPURPOSE: Little is known about hospital readmission among patients <65 years hospitalized with Chronic Obstructive Pulmonary Disease (COPD). We aimed to determine the frequency and predictors of early readmission (within 30 days of discharge) among this population. ⋯ The following authors have nothing to disclose: Roozbeh Sharif, Trisha Parekh, Yong-Fang Kuo, Gulshan SharmaNo Product/Research Disclosure Information.
-
COPD PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Indacaterol is an ultra-long-acting beta-adrenoceptor agonist which needs to be taken once a day, licensed only for the treatment of chronic obstructive pulmonary disease (COPD). It is delivered as an aerosol formulation through a dry powder inhaler. A year-long, placebo-controlled trial published in July 2010 suggests indacaterol may be significantly more effective than twice-daily formoterol in improving FEV1. There were some reductions in the need for rescue medication, but these were not significantly different; nor was there any difference in the rate of exacerbation between the 2 active treatments. We looked at our data regarding the use of Indacaterol in a tertiary care set up. This is a real life experience looking at how Indacaterol influences clinical (MRC dyspnoea scale) and physiological (Spirometry) parameters and exacerbation episodes. ⋯ The following authors have nothing to disclose: Raja Dhar, Sanjit Ray ChaudhuriNo Product/Research Disclosure Information.
-
TransplantationSESSION TYPE: Slide PresentationsPRESENTED ON: Sunday, March 23, 2014 at 12:15 PM - 01:15 PMPURPOSE: In order to identify the characteristics of late-onset non-infectious pulmonary complications (LONIPCs) in children who have undergone allogeneic hematopoietic stem cell transplantation (HSCT), we retrospectively evaluated the incidence, characteristics, and outcomes of LONIPCs in these patients. ⋯ The following authors have nothing to disclose: Jong-seo Yoon, Hwan Soo Kim, Jae Wook Lee, Yoon Hong Chun, Nack Gyun Chung, Hyun Hee Kim, Bin Cho, Hack Ki Kim, Joon Sung LeeNo Product/Research Disclosure Information.